The peroxisome proliferator activated receptor ␣ (PPAR) is a member of the steroid/hormone receptor superfamily that mediates the peroxisome proliferator-dependent transcriptional activation of genes encoding several peroxisomal and microsomal enzymes as well as peroxisome proliferation. Human liver is refractory to the pathological effects of peroxisome proliferators that are seen in mice. With the use of RNase protection assays, the ratio of hepatic PPAR␣ mRNA to ␤-actin mRNA was found to be 1 order of magnitude lower in humans than that observed in mice. In addition, the isolation of human cDNA for PPAR␣ that does not encode a functional PPAR because it lacks exon 6 as a result of alternate RNA splicing suggested that this process might also diminish the expression of PPAR␣. RNase protection analysis of total RNA revealed the presence of splice variants lacking exon 6 at significant levels in all 10 human liver samples examined. Supershift analysis using the CYP4A6-Z peroxisome proliferator response element and antisera specific for PPAR␣ revealed easily detectable amounts of PPAR␣ DNA binding activity in mouse liver lysates, whereas human liver lysates contained Ͼ10-fold lower amounts of PPAR␣ DNA binding activity. In contrast to mouse lysates, the amount of PPAR␣ binding in human lysates was generally less than that of other unidentified proteins. These results suggest that although humans retain the coding potential for a functional receptor, the low levels of PPAR␣ expression in liver may be insufficient to compete effectively with other proteins that bind to peroxisome proliferator response elements.
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A wide range of chemicals that cause an increase in the size and number of peroxisomes and ultimately lead to hepatocarcinogenesis in rodents are collectively known as peroxisome proliferators (Moody et al., 1991; Rao and Reddy, 1987) . The increase in peroxisome size and number is accompanied by increases in peroxisomal fatty acid ␤-oxidation and microsomal -hydroxylation (Sharma et al., 1988) . It has been proposed that the increased levels of H 2 O 2 produced by increased peroxisomal ␤-oxidation leads to DNA damage and tumor formation (Reddy and Rao, 1989) . Moreover, peroxisome proliferators elicit hepatomegaly and hyperplasia, which could contribute to tumorigenesis (Moody et al., 1991; Rao and Reddy, 1987) . These pathological processes are evident in mouse and rat liver but have not been observed to any significant extent in primates (Lock et al., 1989) . Furthermore, unlike in rodent hepatocytes, exposure to peroxisome proliferators did not have any significant effect on the peroxisomal ␤-oxidation in primary cultures of human hepatocytes (Bichet et al., 1990; Blaauboer et al., 1990; Elcombe and Mitchell, 1986) .
The induction of the genes encoding the rat acyl CoA oxidase and the rabbit fatty acid -hydroxylase (CYP4A6) by peroxisome proliferators has been shown to be mediated by a member of the steroid hormone/nuclear receptor superfamily of transcription factors known as the PPAR␣ [individual isoforms of PPAR, THR, and RXR are designated as ␣, ␤, ␥, or ␦. In addition, these designations are preceded by a single letter indicating the species of origin as mouse (m) or human (h)] (Kliewer et al., 1992; Muerhoff et al., 1992; Tugwood et al., 1992) . This receptor is highly conserved between such distant organisms as mouse and frog (Dreyer et al., 1992; Issemann and Green, 1990) , and it has been shown to activate transcription of responsive genes by binding to PPREs as a heterodimer with RXRs (Bardot et al., 1993; Gearing et al., 1993; Keller et al., 1993; Kliewer et al., 1992) . Additional members of the same subfamily as PPAR␣ have been deThis work was supported by United States Public Health Service Grants HD04445 (E.F.J.) and AA08990 (J.R.) and by the American Heart Association, California Affiliate, scribed for several species (PPAR␤, PPAR␥, and PPAR␦) (Dreyer et al., 1992; Kliewer et al., 1994; Schmidt et al., 1992) ; however, these receptors are relatively insensitive to peroxisome proliferators and compared with PPAR␣ are expressed at low or undetectable levels in rodent liver (Braissant et al., 1996; Kliewer et al., 1994) . In addition, the targeted disruption of the mouse PPAR␣ gene has shown that the expression of PPAR␣ is essential for peroxisome proliferator-mediated induction of hepatomegaly, peroxisome proliferation, peroxisomal ␤-oxidation, and microsomal -hydroxylation in mouse liver (Lee et al., 1995) .
Human PPAR␣ cDNAs have been isolated (Mukherjee et al., 1994; Sher et al., 1993) that encode a functional PPAR␣ when tested in heterologous expression studies. The human PPAR␣ exhibits a similar, but not identical, profile of activation by peroxisome proliferators as the murine PPAR␣ (Mukherjee et al., 1994) . These findings demonstrate that humans retain the coding potential for an intact receptor. The high amino acid sequence conservation of the human receptor and its functional similarity with PPAR␣ from other species suggest other causes for the refractory nature of human liver to the pathological effects of peroxisome proliferators. In this report, we characterize the relatively low hepatic expression levels of PPAR␣ in humans relative to levels found in mice, a responsive species exhibiting peroxisome proliferation, and document alternative splicing of a significant fraction of human PPAR␣ RNA resulting in the deletion of exon 6 from the PPAR␣ mRNA and premature termination of the translation product.
Experimental Procedures
Preparation of RNA and RNase protection analysis. Total RNA was prepared from frozen human and CD-1 mouse livers according to the acid guanidinium thiocyanate-phenol-chloroform method (Chomczynski and Sacchi, 1987) . RNase protection analysis was performed as described previously (Shephard et al., 1992) . The riboprobe for mPPAR␣ corresponded to nucleotides 164-504 of the mPPAR␣ cDNA (Issemann and Green, 1990) . The riboprobe for hPPAR␣ corresponded to nucleotides 1239-1455 of the hPPAR␣ cDNA (Sher et al., 1993) . The riboprobe for mouse ␤-actin was derived from a template supplied by Ambion (Austin, TX). The riboprobe for human ␤-actin corresponded to nucleotides 29-183 of the human ␤-actin cDNA. The exon 6ϩ riboprobe corresponded to nucleotides 881-1108 of the hPPAR␣ cDNA (Sher et al., 1993) , whereas a second probe lacking exon 6 contained nucleotides 642-724 (exon 5) and nucleotides 928-1087 (exon 7). Protected fragments were separated by electrophoresis and analyzed using a Molecular Dynamics (Sunnyvale, CA) PhosphorImager SF. The measured intensities for each fragment were corrected for their respective contents of the labeled nucleotide.
Transient transfection experiments. The HepG2 and Huh7 cell lines were obtained from American Type Culture Collection (Rockville, MD) and maintained in DMEM (HepG2) or RPMI-1640 (Huh7) (BioWhittaker, Walkersville, MD) supplemented with 10% fetal calf serum (Gemini, Calabasas, CA). The luciferase reporter plasmid, pLuc-TK-AB , as well as the expression constructs pCMV-PPAR␣, pCMV-PPAR␣-G (Muerhoff et al., 1992) , pRSV-hRXR␣ (Mangelsdorf et al., 1990) , pRSV-hPPAR␣ (Mukherjee et al., 1994) , and pSV␤Gal (Promega, Madison, WI) have been described previously. The reporter and expression constructs were introduced into cells cultured in DMEM through a modification of the calcium phosphate coprecipitation procedure (Sambrook et al., 1989) . After 16 hr, the DNA-containing culture medium was removed, and the cells were washed twice with DMEM and then exposed to culture medium containing Wy-14,643 (pirinixic acid; 50 M) or the equivalent volume of solvent (DMSO, 0.25% v/v final concentration), which was replaced with identical medium after 24 hr. After an additional 24 hr, the cells were harvested, washed with phosphate-buffered saline (0.01 M sodium phosphate, pH 7.4, 0.15 M NaCl), and then lysed by suspension in 0.1 M potassium phosphate buffer, pH 7.8, containing 1 mM dithiothreitol and 0.05% Triton X-100 followed by three cycles of freezing and thawing. Insoluble material was removed by centrifugation, and luciferase activity was determined using a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, CA). ␤-Galactosidase activities were determined as described previously (Muerhoff et al., 1992) . The luciferase activity obtained for individual cultures was expressed relative to the ␤-galactosidase activity obtained for the same lysate preparation.
Preparation of liver lysates and supershift analysis. Frozen liver sections from 3 CD-1 or 3 Balb/C mice as well as 20 human liver samples were thawed and homogenized in phosphate-buffered saline solution containing 5 mM EDTA, 1 mM dithiothreitol, 0.2 mM 4-(2-aminoethyl)benzenesulfonylfluoride (Calbiochem, San Diego, CA), 1 g/ml leupeptin, 1 g/ml aprotinin, and 10% glycerol. The homogenates were then sonicated for 10 sec and centrifuged at 75,000 rpm in a Beckman Instruments (Palo Alto, CA) model TL-100 ultracentrifuge for 30 min at 4°. The protein content of the supernatant was determined using the BioRad Protein Assay (Bradford assay; Hercules, CA). For supershift analysis, 30 l of lysate was combined with 1 g (1 l) of poly(dI/dC) and 1 g (1 l) of sheared salmon sperm DNA and incubated on ice for 10 min. After the addition of 25 fmol of radiolabeled, gel-purified, double-stranded oligonucleotide, the incubation was continued on ice for 10 min, after which 1 l of either rabbit preimmune, rabbit anti-PPAR␣ , anti-RXR serum (a gift from R. Evans, Salk Institute for Biological Studies, La Jolla, CA), rabbit anti-ARP-1 serum (a gift from S. Malik, American Cyanamid, Pearl River, NY), or mouse monoclonal anti-THR␤1 antibody (clone J52; Affinity Bioreagents, Neshanic Station, NJ) was added, and the incubation was continued for an additional 30 min. After the addition of 1 l of loading buffer (30% glycerol, 5 mg/ml bovine serum albumin, 0.005% bromphenol blue), the reaction mixture was loaded onto a 4% acrylamide/0.05% bisacrylamide gel containing 45 mM Tris borate buffer, pH 8.0, 1 mM EDTA, and 1.25% glycerol. Electrophoresis was performed at 160 V for 90 min at 4°. The gel was then dried and analyzed using a Molecular Dynamics PhosphorImager SF. For competition experiments, a 10-200-fold excess of competing oligonucleotide was added to the reaction.
EMSAs using in vitro transcribed/translated PPARs and RXR␣. Supercoiled plasmids containing the cDNAs corresponding to mouse PPAR␣ (Muerhoff et al., 1992) , PPAR␥1 (Kliewer et al., 1994) , human PPAR␣ (Mukherjee et al., 1994) , Nuc1 (PPAR␦) (Schmidt et al., 1992) , and RXR␣ (Mangelsdorf et al., 1990) were used for in vitro transcription/translation in a TNT-coupled rabbit reticulocyte lysate system (Promega) at 30°for 90 min. Lysates containing each of the PPARs (1 l) and/or human RXR␣ (1 l) were incubated for 30 min at room temperature with 10 fmol of radiolabeled, gel-purified, double-stranded probe in 10 mM Tris, pH 8.0, 150 mM KCl, 6% glycerol, 0.05% Nonidet P-40, 1 mM dithiothreitol, and 125 ng/l poly(dI/dC) and then electrophoresed through a 4% polyacrylamide (37.5:1) gel containing 45 mM Tris borate buffer, pH 8.0, 1 mM EDTA, and 1.25% glycerol at 130 V for 100 min at room temperature. When supershift assays were performed, 1 l of rabbit anti-PPAR␣ serum was added to the reaction.
Human liver specimens. Human liver samples were obtained from the Liver Tissue Procurement and Distribution System (University of Minnesota, Minneapolis, MN), the International Institute for the Advancement of Medicine (Exton, PA), and the National Diabetes Research Interchange (Philadelphia, PA). All livers were frozen in liquid nitrogen within 10 hr of death, shipped overnight on dry ice, and stored at Ϫ70°until lysates were prepared. All tissue Peroxisome Proliferator Activated Receptor-␣ Expression samples seemed to be in good condition. In some cases, low or moderate degrees of fatty liver were noted as indicated (see Table 2 ).
Results
RNA was prepared from human and mouse liver, as well as from two human hepatoma-derived cell lines, HepG2 and Huh7, and the human breast carcinoma cell line T47D. These RNA samples were analyzed by RNase protection to determine PPAR␣ mRNA levels. As shown in Fig. 1 , top, the different exposure times and relative band intensities clearly indicate that human liver contains very low PPAR␣ mRNA levels that are approximately 1 order of magnitude lower than those observed in mouse liver. This difference is unlikely to reflect a poor recovery of mRNA from the human liver samples because the levels of ␤-actin mRNA are similar in the mouse and human liver samples. PhosphorImager quantification of gels revealed that relative to ␤-actin, Huh7 cells contain levels of PPAR␣ mRNA that approximate those seen in human liver, whereas HepG2 cells contain 4-fold lower levels, and T47D cells had no detectable PPAR␣ mRNA (Fig. 1, bottom) . In contrast, mouse liver lysates displayed significantly greater amounts of PPAR␣ mRNA relative to ␤-actin.
When Huh7 or HepG2 cells are transfected with a peroxisome proliferator responsive reporter plasmid using the acylCoA oxidase PPRE upstream of the thymidine kinase promoter (pLuc-TK-AB), neither cell line displayed significant peroxisome proliferator-dependent luciferase expression (Fig. 2, pRSV and pCMV) . However, cotransfection with expression plasmids containing cDNA for either human PPAR␣ or murine PPAR␣ led to a significant increase in the expression of the reporter gene in both cell lines without the addition of peroxisome proliferator to the medium (intrinsic activation). As reported previously, both receptors exhibit peroxisome proliferator-dependent transactivation in HepG2 cells Mukherjee et al., 1994) . Although mPPAR␣ exhibited a peroxisome proliferator-dependent transactivation in Huh7 cells, the intrinsic activation of hP-PAR␣ in this cell line is too great to see a significant, additional increase of transcription in the presence of Wy-14,643. A mutant of mPPAR␣ bearing a glycine substitution for Glu284, PPAR␣-E284G, exhibits a much lower intrinsic activation, which may be related to a reduced affinity for agonists Forman et al., 1997) . As shown in Fig.  2 , expression of this PPAR in both cell lines reduced the degree of intrinsic activation and led to a greater effect of peroxisome proliferator on reporter gene expression. These results demonstrate that these human liver derived cell lines contain insufficient amounts of PPAR␣ to fully activate transcription of the reporter and are unable to respond measurably when exposed to added peroxisome proliferators. However, supplementation of PPAR␣ levels with either the murine or human receptor by heterologous expression dramatically increases transactivation of the reporter.
The potential that alternate processing of the human PPAR␣ RNA might further diminish PPAR␣ expression was suggested by the isolation from a human kidney cDNA library of a cDNA (hPPARsv) 2 that spanned the entire coding sequence of hPPAR␣ but lacked sequences encoding exon 2 and exon 6 (Fig. 3A) based on the organization of the mouse PPAR␣ gene (Gearing et al., 1994) . Exon 2 is part of the 5Ј noncoding region, whereas exon 6 encodes a segment of the receptor polypeptide between the putative DNA and ligandbinding domains. Sequence analysis indicates that a frame shift terminates translation of the peptide immediately after the zinc finger domain of the receptor and before the carboxyl-terminal extension that participates in the binding of mP-PAR␣ to PPREs (Hsu MH, Palmer CNA, Song W, Griffin KJ, and Johnson EF, manuscript in preparation). RNase protection assays were used to determine the existence and prevalence of this splicing variation for PPAR␣ mRNA in human liver samples (Fig. 4) . Total RNA was prepared from 10 human liver samples, and 30 g of each was assayed for PPAR␣ mRNA levels by RNase protection with a riboprobe derived from wild-type human PPAR␣ that spans the junction of exons 6 and 7 (Fig. 3B) . A 228-nucleotide protected fragment is expected from RNase digestion of hybrids formed between the probe and properly processed mRNA (exon6ϩ), and a 181-nucleotide protected fragment is expected for hybrids with splice variants that lack the portion of the probe corresponding to exon 6 (exon6Ϫ). Fragments corresponding to hybrids formed with transcripts contain exon 6 and those that do not are evident for RNA preparations from all 10 individuals (Fig. 4) . Table 1 summarizes the relative expression levels of both the intact and altered mRNAs in each of the human liver samples as quantified using a PhosphorImager and corrected for the respective contents of radionucleotide in each fragment. These results indicate the consistent presence of both mRNA species with a 3-fold interindividual variation in the expression level of the functional mRNA and less variation observed for the misspliced mRNA. The latter accounts for 28 -42% of the protected fragments in each sample. Additional experiments (not shown) demonstrated that a probe corresponding to the sequence of the hPPARsv cDNA across the exon5/exon7 junction was protected, confirming the presence of the splice variant identified by the cDNA.
The low levels of PPAR␣ in human liver lysates precluded the use of Western blots to examine the expression of PPAR␣ protein. To increase sensitivity, human and mouse liver lysates were analyzed for binding to a 32 P-labeled doublestranded oligonucleotide corresponding to the CYP4A6 Z PPRE using an EMSA. Assays were done in the absence of serum or in the presence of either preimmune, anti-mPPAR␣ serum or antibody to hRXRs that are binding partners for PPARs. The anti-PPAR␣ serum was raised against mouse PPAR␣ , and it also recognizes human PPAR␣. As shown in Fig. 5 , top, inclusion of PPAR␣ antiserum greatly diminishes the amount of in vitro translated human or mouse PPAR␣/RXR complexes without appreciably affecting complexes containing NucI (PPAR␦) or PPAR␥, reflecting antibody specificity for the PPAR␣ isoform. As expected, the antibody to RXR inhibits complex formation of all three PPARs (data not shown). The preimmune serum collected before PPAR␣ antigen presentation does not affect PPAR␣/RXR heterodimer complex mobility.
Several electrophoretically distinct CYP4A6-Z PPRE protein complexes are evident for mouse and human liver lysates. Formation of the principal complex (Fig. 5, bottom, I ) is extensively inhibited by the anti-mPPAR␣ sera. Supershift experiments using anti-RXR antibody yielded results for complex I similar to those obtained with anti-PPAR␣. However, when human liver lysates were used, the RXR antibody exhibited a slightly greater inhibition in complex I formation, Ϸ125%, than that seen for anti-PPAR␣, suggesting that other RXR heterodimers, possibly including PPAR␥ or PPAR␦, could be contributing to complex I in human liver lysates. The residual complex I that is not affected by either of the antibodies to PPAR␣ or RXR suggests that other binding proteins form complexes with similar mobility to that of Top, total RNA was prepared from mouse and human liver samples, and 15 g was hybridized with 32 P-labeled antisense riboprobes specific for human or mouse PPAR␣. The samples were then subjected to RNase digestion and electrophoresed through a 6% acrylamide/8 M urea gel. The protected fragments were visualized by autoradiography.
35
S-Labeled 1-kb ladder was included as a molecular weight marker (STD). A protection assay of yeast total RNA (YEAST) shows complete digestion of the probe. PROBE, undigested riboprobe. EXP, autoradiographic exposure time. Bottom, the level of PPAR␣ mRNA in each sample is expressed as a percentage of fully protected ␤-actin mRNA. A Molecular Dynamics PhosphorImager was used to analyze RNase protection assays of total RNA prepared from either human and mouse liver (CD-1 strain) or from two human liver-derived cell lines, HepG2 and Huh7, and from the human breast cancer cell line T47D. The radioactivity of protected probe in each assay was determined by comparison with a standard curve of undigested riboprobe. The signal obtained with the PPAR␣ riboprobe was normalized with the signal obtained for the same sample with a ␤-actin riboprobe. Fig. 2 . Effect of PPAR␣ expression on reporter gene transcription in human liver cell lines. Huh7 and HepG2 cell lines were cotransfected with pSV␤Gal, pLuc-TK-AB, and either pCMV (CMV), pCMV-mPPAR-E284G (mPPAR-G), pCMV-mPPAR␣ (mPPAR), pRSV, or pRSV-hPPAR␣ (hPPAR). After incubation with DNA for 16 hr, the cells were washed and then solvent (DMSO; Ⅺ) or Wy-14,643 (f) was added in fresh medium for an additional 48-hr incubation. Individual luciferase activities were normalized to the ␤-galactosidase activity determined for the same sample and were expressed relative to the value obtained in the presence of DMSO for the pCMV expression vector without a cDNA insert. Values are mean plus standard deviation obtained from three independent transfections.
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at ASPET Journals on October 28, 2017 molpharm.aspetjournals.org PPAR␣/RXR heterodimers. A second complex, II, was also detected that was not affected by anti-RXR or anti-PPAR␣ sera. Complex II is more prominent in some human liver samples than complex I (Fig. 6 , human liver samples H and R). Antibodies to nuclear receptors that recognize binding sites similar to PPREs, such as ARP-1 or THR␤ (Fig. 5 , bottom) as well as hepatocyte nuclear factor 4 or chicken ovalbumin upstream promotor transcription factor (data not shown), did not affect the intensity of either complex I or II.
The human liver lysate used in the experiment depicted in Fig. 5 , bottom, exhibited the highest amount of PPAR␣/RXR complex of the 20 samples tested. This was determined by subtracting the intensity of complex I determined in the presence of antibody to PPAR␣ from the intensity of the band determined in the presence of preimmune serum in the same experiment. In all experiments, intensities were measured using a PhosphoImager and were expressed relative to the intensity of complex I for human liver K determined in the presence of preimmune serum in the same experiment. As shown in Table 2 , Ϸ80% of complex I was shifted for each of six samples from mice, and the intensities of the mouse complex I band determined in the presence of preimmune serum was Ϸ5-fold that of the human reference, sample K (Fig. 5, bottom) . The human samples showed a much greater variation. In 3 of 20 samples, significant complex formation could not be measured. In 10 of 20 samples, a significant effect of the antiserum to PPAR␣ could not be detected (Ͻ20%), although complex I was evident. The remaining 7 Fig. 3 . hPPARsv cDNA and the RNase protection probe used to characterize alternative RNA processing. A, The entire coding sequence of mPPAR␣ was used to screen a human kidney cDNA library. Several partial clones encoding hPPAR␣ were identified. The diagram shows the structure of one cDNA (hPPARsv) that spanned the entire coding sequence of the hPPAR␣ but lacked sequences corresponding to exons 2 and 6 when compared with the genomic structure of mouse PPAR␣ (Gearing et al., 1994) . Exon 2 is part of the 5Ј noncoding region, and exon 6 encodes a segment of the receptor polypeptide between the putative DNA and ligand binding domains (DBD and LBD, respectively) . The deletion of exon 6 is predicted to result in a frame shift that terminates translation of the peptide immediately after the zinc finger region of the DNA binding domain. B, Location of the exon6ϩ RNase protection probe relative to the exon 6 deletion. Fig. 4 . Analysis of the expression of the PPAR␣ mRNA exon 6Ϫ splice variant. Total RNA (30 g) from 10 human liver samples was assayed for PPAR␣ mRNA levels by RNase protection with the exon6ϩ probe. The products of a sequencing reaction across the exon6ϩ probe using a primer corresponding to the terminus of the probe served as a reference. Left, predicted cleavage sites indicated by the expected size of each protected fragment. A 228-nucleotide band is expected for hybrids formed with the wild-type mRNA containing exon 6, and a 181-nucleotide band is predicted for hybrids formed with splice variants lacking exon 6. probe, undigested probe of 302 nucleotides. tRNA, complete digestion of the probe in the presence of yeast tRNA. samples exhibited intensities for complex I similar to that of human sample K (Fig. 5, bottom) . In these samples, the antibody to PPAR␣ diminished complex I formation by an average of 41%. Thus, in the 7 lysates in which PPAR␣ could be detected by the assay, the amounts were Ϸ10-fold lower than those detected in mouse liver, and in the remainder of the samples the amount was below the level of detection (Ͼ20-fold less than mouse liver). Competition experiments using increasing amounts of unlabeled CYP4A6-Z PPRE indicate the presence of both high and low affinity binding components in complex I (not shown). The estimated amount of the high affinity binding component is similar to the amount shifted by anti-PPAR␣ and is not seen in samples in which the anti-PPAR␣ does not diminish complex I, suggesting that the residual proteins in complex I are likely to bind with a lower affinity than PPAR␣/RXR.
To examine the competence of human liver lysates to support significant DNA binding in the presence of adequate amounts of PPAR␣, in vitro transcribed/translated human PPAR␣ was added into human liver lysates H and R that displayed undetectable or low amounts of complex I for the 5 . Supershift analysis of PPAR␣ and RXR in mouse and human liver lysates. Top, the anti-PPAR␣ serum alters the mobility of both mouse and human PPAR␣/RXR (P/R) heterodimers but not those of mouse PPAR␥1 or human NucI using in vitro translated proteins in an EMSA. probe, 32 P-labeled CYP4A6-Z . Bottom, human (K; Table 2) (225 g of protein) and CD-1 mouse (150 g of protein) liver lysates were analyzed for binding to 32 P-labeled double-stranded oligonucleotides corresponding to the CYP4A6-Z PPRE using an EMSA. Shown are assays done in the absence of serum or presence of preimmune, anti-PPAR␣, anti-RXR, anti-ARP-1, or anti-THR␤ serum. I, Mobility of the band containing PPAR␣/RXR complexes. II, Unidentified complex of slower mobility formed with the CYP4A6-Z oligonucleotide. Fig. 6 . Addition of in vitro translated PPAR␣ to human liver lysates in EMSA. In the absence of in vitro translated PPAR␣, CD-1 mouse liver (ML) lysate (100 g of protein) and human liver lysate K (HL-K, 150 g of protein) form PPAR␣/RXR heterodimer complexes (I) with the CYP4A6-Z PPRE. In contrast, human liver lysate H (HL-H, 100 g of protein) and human liver lysate R (HL-R, 35 g of protein) do not. When 1 l of in vitro translated PPAR␣ (P) is added to human liver lysates H and R, the intensity of the PPAR␣/RXR complexes is greatly increased.
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at ASPET Journals on October 28, 2017 molpharm.aspetjournals.org conditions used in Fig. 6 . Supplementation of these samples with hPPAR␣ protein produced by in vitro transcription/ translation greatly increased the amount of CYP4A6-Z PPRE binding activity (Fig. 6, ϩP) . This effect of hPPAR␣ supplementation on binding is consistent with the transcriptional increase observed in hepatoma cells transfected with an expression vector for hPPAR␣ to augment cellular expression of the receptor (Fig. 2) . This observation further supports the hypothesis that the low levels of PPAR␣ expression, rather than the absence or imperfection of other required accessory factors, may be insufficient to evoke the pathological effects of peroxisome proliferator exposure in human liver.
Discussion
The murine PPAR␣ has been shown to mediate the peroxisome proliferator-dependent transcriptional activation of the genes encoding several hepatic enzymes, including the acyl CoA oxidase and fatty acid -hydroxylases (Kliewer et al., 1992; Muerhoff et al., 1992; Tugwood et al., 1992) . Previous studies indicate that primary cultures of human hepatocytes do not display measurable peroxisome proliferator-dependent induction of these enzyme activities or peroxisome proliferation (Bichet et al., 1990; Blaauboer et al., 1990; Elcombe and Mitchell, 1986) . Other investigators have demonstrated that humans retain the capacity to encode functional PPAR␣ (Mukherjee et al., 1994; Sher et al., 1993) . In this report, we have shown that human liver contains 10-fold lower levels of PPAR␣ mRNA compared with the highly responsive mouse liver and that a fraction of this mRNA lacks exon 6 and does not encode a functional receptor. A report from a recent meeting (Tugwood et al., 1996) describes the isolation through polymerase chain reaction of several variant PPAR␣ cDNAs from human biopsy samples, including one that lacks exon 6. Although the data were not shown, RNase protection assays were reported to detect the presence of this misspliced RNA in all 10 human liver samples that were tested, which is concordant with our results. However, the abundance of the splice variant RNA was estimated to be Ն1 order of magnitude below the level of the full-length transcript. In contrast, our results suggest higher levels for variant RNAs lacking exon 6 (Table 1) . Detection of the splice variant in all of the individuals examined suggests that exon skipping is associated with the processing of the human 
a The amounts of complex I obtained for each liver lysate with the labeled CYP4A6 Z element in the presence of preimmune serum or anti-PPAR␣ serum was measured using a PhosphorImager and electrophoretic mobility shift assays. The results were normalized on the basis of total protein in the sample and are expressed relative to the value obtained for human liver lysate K in the presence of preimmune serum.
b The percentage is the difference obtained by subtracting the amount of complex I determined in the presence of anti-PPAR␣ from the amount found in the presence of preimmune serum and is expressed as a percentage of the amount obtained in the presence of the preimmune serum.
c Values are given as mean Ϯ standard deviation with number of samples in parentheses. d Sample identifiers correspond to samples depicted in Fig. 4 -6 and Table 1 . e Clinical history: ALC, alcohol; FL, moderate fatty liver; DB, diabetes (type II); Rx, medications (human B, phenytoin, labetolol, furosamide, verapamil, dexamethasone, ranitidine, vasopressin; human C, loop diuretic predisone, vasotec; human D, phenytoin, cimetidine, insulin, cephalosporin (Ancef); human G, cocaine; human M, gemfibrozil, estrogen, tolbutamide, tricyclic antidepressant, aspirin, cardiofem nitrate; human N, allopurinal, cephalosporin, methylprednisone).
f NRM indicates that the following liver function tests were performed: total bilirubin, glutamate oxaloacetate transferase, glutamate pyruvate transferase, lactate dehydrogenase, and prothrombin time. The samples displayed normal levels. In some cases (ELV), levels above normal ranges were found in some of the tests. The elevated enzyme levels are probably due to the injury rather than to poor liver function. DM indicates that microsomes were prepared from the tissue sample and were used successfully for kinetic assays to determine P450 2C8, 2C9, 2C18, 2C19, and 3A catalytic activity (Jung et al., 1997) . N.A., not available.
g N.S., the percent difference is less than the interassay variation for the signal intensity. h N.D., the signal intensity is less than twice background levels.
PPAR␣ pre-mRNA and that it does not reflect a rare allele. Exon skipping has been observed for transcripts of other genes and often leads to circular RNAs formed by the excised exons (Zaphiropoulos, 1997) . However, neither the mechanisms leading to the excision of the exon and the formation of the circular RNA nor the factors that contribute to this process have been clearly defined. Using supershift analysis of human and mouse liver lysates, we demonstrated that the CYP4A6 PPRE mainly forms complexes that contain PPAR␣ with mouse liver lysates but not with human liver lysates. Direct comparisons of the amount of complex shifted by PPAR␣ antibodies indicates that mouse liver lysates contain Ն1 order of magnitude more PPAR␣ protein than human lysates. Reduced expression levels of functional human PPAR␣ could allow PPREs to be occupied in vivo by other nuclear receptors that bind to similar sequences, such as homodimers of RXR, ARP-1, or hepatocyte nuclear factor 4, and thus affect responsiveness to peroxisome proliferators. The lack of significant increases in smooth endoplasmic reticulum, number of peroxisomes, or enzyme induction as a result of peroxisome proliferator exposure observed in human hepatocytes is not due to an absence of functional PPAR␣ but may reflect insufficient levels of PPAR␣ to impose a response over other signaling pathways. This is corroborated by the finding that proteins other than PPAR␣ contribute to the formation of complex I detected by EMSA as well as to a second electrophoretically distinct complex, II. These proteins predominate over the amount of PPAR␣/RXR in most human samples, and although they may bind with lower affinity, these proteins may compete more effectively with PPAR␣/RXR for binding to PPREs in human liver due to the relatively lower expression of PPAR␣ compared with the levels found in mice. Supplementation of the level of PPAR␣ in human liver lysates does confer significant PPRE binding activity, suggesting that sufficient levels of ancillary factors are present to support increased PPAR␣ binding. Thus, under normal conditions, the low level of PPAR␣ expression could make a primary contribution to human liver being refractory to the pathological effects of peroxisome proliferator exposure. It is not known whether PPAR␣ expression can be induced by as-yetunidentified factors in human liver as it is in rat liver by glucocorticoids (Lemberger et al., 1994) . If so, elevated expression of hPPAR␣ may increase the sensitivity of human liver to peroxisome proliferators.
Although the concentrations of PPAR␣ seem to be low in human liver relative to mouse liver, the receptor is present and could modulate the expression of some genes. Fibrate drugs that are PPAR␣ agonists are used therapeutically to lower serum triglycerides, and the induction of lipoprotein lipases and apolipoproteins are thought to contribute to these effects. PPREs have been characterized in the 5Ј flanking sequences of the human lipoprotein lipase (Schoonjans et al., 1996) and apolipoprotein AII genes (Vu-Dac et al., 1995) as well as in the human peroxisomal acyl CoA oxidase gene (Varanasi et al., 1996) . Although other tissues can contribute to the production of the lipoprotein lipase (Schoonjans et al., 1996) , the expression of the apolipoprotein AII is largely restricted to liver and intestine (Vu-Dac et al., 1995) . Fibrates have been reported to induce the expression of apolipoprotein AII in HepG2 cells as well as in primary cultures of human hepatocytes, whereas significant effects were not evident for the acyl CoA oxidase (Vu-Dac et al., 1995) . As shown here, the levels of PPAR␣ mRNAs are very low in HepG2 cells, and they are not adequate to regulate reporter gene transcription driven by the PPREs from the rat acyl CoA oxidase or P450 4A6 genes . Whether these differences reflect characteristics of the PPREs or other pathways are involved is unclear. The lower levels of expression in human liver may permit PPAR␣ to mediate some therapeutic responses to fibrates but limit the large, persistent, and extensive pathological changes that are observed in mice that involve the increased expression of a wider range genes.
